Altimmune (ALT) Gains from Sales and Divestitures (2017 - 2025)
Altimmune (ALT) reported Gains from Sales and Divestitures of $286653.0 for Q4 2025, down 0.8% year-over-year from $288977.0 in Q4 2024, and up 7.0% on a QoQ basis from $267903.0 in Q3 2025.
Altimmune (ALT) has 9 years of Gains from Sales and Divestitures data on file, last reported at $286653.0 in Q4 2025.
- Quarterly Gains from Sales and Divestitures fell 0.8% year-over-year to $286653.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $286653.0 (down 0.8% YoY) and the FY2025 annual result came in at $286653.0, down 0.8% from the prior year.
- Gains from Sales and Divestitures advanced to $286653.0 in Q4 2025 per ALT's latest filing, from $267903.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $288977.0 in Q4 2024 and bottomed at $4687.0 in Q4 2021.
- The 5-year median for Gains from Sales and Divestitures is $107830.0 (2023), against an average of $158523.7.
- The widest annual swing landed in 2021, when Gains from Sales and Divestitures sank 95.72%; it then jumped 1478.84% in 2022.
- Tracing ALT's Gains from Sales and Divestitures over 5 years: stood at $4687.0 in 2021, then jumped by 1478.84% to $74000.0 in 2022, then soared by 55.43% to $115018.0 in 2023, then surged by 151.25% to $288977.0 in 2024, then declined by 0.8% to $286653.0 in 2025.
- Per Business Quant, the three latest ALT Gains from Sales and Divestitures figures stand at $286653.0 (Q4 2025), $267903.0 (Q3 2025), and $288977.0 (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 286,653.00 |
| Dec 31, 2025 | 286,653.00 |
| Sep 30, 2025 | 267,903.00 |
| Sep 30, 2025 | 267,903.00 |
| Dec 31, 2024 | 288,977.00 |
| Dec 31, 2024 | 288,977.00 |
| Sep 30, 2024 | 288,040.00 |
| Sep 30, 2024 | 288,040.00 |
| Jun 30, 2024 | 286,165.00 |
| Jun 30, 2024 | 286,165.00 |
| Dec 31, 2023 | 115,018.00 |
| Dec 31, 2023 | 115,018.00 |
| Sep 30, 2023 | 100,642.00 |
| Sep 30, 2023 | 100,642.00 |
| Jun 30, 2023 | 98,768.00 |
| Jun 30, 2023 | 98,768.00 |
| Dec 31, 2022 | 74,000.00 |
| Dec 31, 2022 | 74,000.00 |
| Sep 30, 2022 | 46,653.00 |
| Sep 30, 2022 | 46,653.00 |
| Jun 30, 2022 | 44,778.00 |
| Jun 30, 2022 | 44,778.00 |
| Dec 31, 2021 | 4,687.00 |
| Dec 31, 2021 | 4,687.00 |
| Dec 31, 2020 | 109,525.00 |
| Dec 31, 2020 | 109,525.00 |
| Dec 31, 2019 | 87,738.00 |
| Dec 31, 2019 | 87,738.00 |
| Dec 31, 2018 | 284.00 |
| Dec 31, 2018 | 284.00 |
| Dec 31, 2017 | 51,118.00 |
| Dec 31, 2017 | 51,118.00 |